EnucASCs for bone regeneration

Despite decades of research and advancements in bone regeneration, non-healing fractures remain a significant challenge for patients and the healthcare system. With an aging population and the increasing prevalence of bone diseases such as osteoporosis, the burden of non-healing fractures is expected to persist, underscoring the urgent need for innovative therapeutic solutions. Current treatment options, including surgical interventions and bone fixation, often fall short of achieving complete fracture healing and may even compromise patient well-being. While advances in tissue regeneration have introduced promising alternativessuch as scaffolds, growth factors, and stem cell therapieseach approach faces critical limitations, including issues with bioavailability, efficiency, and safety. In response to these challenges, we are proud to introduce a groundbreaking technology platform that combines the strengths of existing strategies while overcoming their drawbacks. Our solution leverages enucleated mesenchymal stem/stromal cells (MSCs), also termed Cargocytes, to deliver a next- generation therapeutic approach for bone regeneration. Cargocytes are engineered, enucleated cells that function as large vesicles, free of nuclear DNA and incapable of replication. These cells retain the ability to secrete natural pro-regenerative factors and can be further engineered to overexpress therapeutic growth factors. This innovative approach offers a safer and more effective alternative to traditional stem cell or extracellular vesicle (EV)-based therapies. By combining pro-osteogenic growth factors with the unique properties of Cargocytes, we aim to drive bone regeneration. Our approach is designed to deliver active bone-anabolic factors in sufficient quantities to induce a robust pro-osteogenic response, without the risks of unwanted differentiation or inflammation. The limited lifespan of Cargocytes is a critical advantage, as it allows for a transient yet powerful boost to the early phases of bone healing. Importantly, by removing the cells` nuclei, this therapy is positioned as a complex biopharmaceutical solution rather than an advanced therapy medicinal product (ATMP), streamlining its path to clinical application. If successful, this innovative platform will not only transform the field of bone regeneration but also demonstrate the versatility of Cargocyte-based technology for addressing a wide range of high-need clinical indications. We are excited to advance this cutting-edge research and look forward to the potential impact it could have in the future.